Physician profile
Birendra Kumar
NPI 1063491066
$8,461.25
in general payments reported to CMS, 2019-2025
14 companies · $2,138 in 2025
The $2,138 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,199 · 2021: $2,290 · 2022: $613 · 2024: $1,222 · 2025: $2,138.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,077 · Honoraria: $1,200 · Education: $48.17 · Food and Beverage: $35.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,077.11 |
| Honoraria | $1,200.00 |
| Education | $48.17 |
| Food and Beverage | $35.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $2,198.64 | 2019 | |
| Karyopharm Therapeutics INC. | $2,112.11 | 2025 | Xpovio |
| Incyte Corporation | $1,440.00 | 2021 | |
| Pfizer INC. | $1,226.00 | 2024-2025 | |
| Glaxosmithkline, LLC. | $825.00 | 2021 | |
| Beigene USA, INC. | $525.00 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $87.50 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $16.06 | 2024 | Reblozyl |
| Nabriva Therapeutics, Plc | $12.91 | 2021 | |
| Gilead Sciences, INC. | $11.92 | 2021 | |
| Rigel Pharmaceuticals, INC. | $6.11 | 2024 | Rezlidhia, Tavalisse |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Birendra Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.